Approval · Notice of Compliance 37832 · 2026
IMFINZI: Notice of Compliance 37832
Issued July 3, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 37832
- Date
- July 3, 2026
- Company
- Astrazeneca Canada IncMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Change in release testing procedure
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| IMFINZI | Not yet assigned | — |
Medicinal ingredients
- DURVALUMAB 50 MG per ML